Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Oligonucleotide Stories

2012-02-28 10:45:48

Antisense oligonucleotides — short segments of genetic material designed to target specific areas of a gene or chromosome — that activated an enzyme to "chew up" toxic RNA (ribonucleic acid) could point the way to a treatment for a degenerative muscle disease called myotonic dystrophy, said researchers from Baylor College of Medicine and Isis Pharmaceuticals, Inc., in a report in the journal Proceedings of the National Academy of Sciences. "This is a proof-of-principle therapy...

2012-02-22 09:17:00

BASKING RIDGE, N.J., Feb. 22, 2012 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the Citi 2012 Global Health Care Conference at 8:30 a.m. EST on February 29, 2012 at The Waldorf Astoria in New York, NY. The presentation will include an overview of the Company's pipeline with emphasis on the lead...

2011-09-28 09:17:00

BASKING RIDGE, N.J., Sept. 28, 2011 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the Sofinnova Japan Biopharma Partnering Conference at 2:50 p.m. JST on October 4, 2011 in Tokyo, Japan. The presentation will include an overview of the Company's pipeline with emphasis on the lead development program, the innovative...

2011-09-14 09:17:00

BASKING RIDGE, N.J., Sept. 14, 2011 /PRNewswire/ -- Regado Biosciences, a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced that Ellen McDonald, MBA, Senior Vice President and Chief Business Officer, will be presenting at the Annual UBS Global Life Sciences Conference at the Grand Hyatt New York in New York City on Wednesday, September 21, 2011 at 3:30 p.m. EDT. The presentation will include an overview of the Company's...

2011-05-27 08:47:00

SAN DIEGO, May 27, 2011 /PRNewswire/ -- TriLink BioTechnologies, Inc. (TriLink), a leader in manufacturing high quality oligonucleotides and nucleoside triphosphates, announced today the award of their CleanAmp(TM) Primer patent by the European Patent Office (EPO Patent no. 2032714). First launched in March of 2008, CleanAmp(TM) Primers pioneered TriLink's CleanAmp(TM) line of next generation Hot Start PCR products. The technology consists of thermolabile chemical modifications which...

2011-03-30 09:17:00

BASKING RIDGE, N.J., March 30, 2011 /PRNewswire/ -- Regado Biosciences, a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the Needham & Company's 10th Annual Healthcare Conference at the New York Palace Hotel in New York City on Wednesday, April 6, 2011 at 11:20 a.m. EDT. The presentation will include an overview of the Company's pipeline with emphasis...

2011-03-28 11:09:00

BASKING RIDGE, N.J., March 28, 2011 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced that Thomas J. Povsic, MD, PhD, Assistant Professor of Medicine at Duke University, will present results of the RADAR Phase 2b clinical trial for the Company's lead product, the REG1 anticoagulation system, at the i2 Summit during the American College of Cardiology 2011 60th Annual Scientific...

2011-02-23 09:17:00

BASKING RIDGE, N.J., Feb. 23, 2011 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Ellen McDonald, MBA, Senior Vice President and Chief Business Officer, will be speaking and participating on a panel that will highlight new and innovative cardiovascular drug therapies at the 2011 RBC Capital Markets Healthcare Conference. The panel discussion will be held at the New York Palace Hotel...

2010-11-23 09:17:00

BASKING RIDGE, N.J., Nov. 23, 2010 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the 22nd Annual Piper Jaffray Health Care Conference. Dr. Mazzo's presentation will be given at the New York Palace Hotel in the Kennedy 2 Room in New York City on Tuesday, November 30, 2010 at 9:30 a.m. EST. Additionally, Dr. Mazzo will be...

2010-11-17 09:30:00

BASKING RIDGE, N.J., Nov. 17, 2010 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Steven L. Zelenkofske, D.O., F.A.C.C., Senior Vice President and Chief Medical Officer, and Chris Rusconi, Ph.D., Senior Vice President and Chief Scientific Officer, presented a poster about REG3 at the AHA Scientific Sessions meeting on November 17, 2010 at 9:30 a.m. CST in Chicago, IL. The...